Nanomix Corporation announced that it has entered into an exclusive distribution agreement with Woodley Equipment Company Ltd. (Woodley). Under the agreement, Woodley will work with Nanomix to develop species specific ranges for the S1 critical infection panel and distribute the eLab system in the veterinary market for regions outside of the United States. Sepsis is one of the most important causes of morbidity and mortality in humans and it is also associated with high mortality rates in dogs and cats.

Sepsis can develop if an animal is affected by an infection that is left untreated or undertreated. The infection may originate in many different areas contributing to the difficulty in diagnosis, for example, in the ears or even in the skin. The Nanomix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing.

The Nanomix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type.

The assay runs on the eLab® Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.